X4 Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

X4 Pharmaceuticals, Inc

Received Nasdaq letter on Nov 13, 2023 for non-compliance with minimum $1.00 bid price rule.
Common stock closing bid price below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until May 13, 2024, to regain compliance.
If not compliant by deadline, may request additional 180 days if other listing standards are met.
Considering potential reverse stock split to cure deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.